Cellectar Biosciences, Inc. - Common Stock (NQ:CLRB)

Cellectar Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates

November 10, 2026

Cellectar Biosciences to Present Three Posters Highlighting Durable Clinical Activity of Iopofosine I 131 in Waldenström Macroglobulinemia at the American Society of Hematology Annual Meeting and Exposition

Performance

52-Week Range 74.3% below 52-week high

1.210

1.1152W Low 4.7052W High

1 Week 11.7% below 1-week high

1.111W Low 1.371W High

Cellectar Biosciences, Inc. - Common Stock (CLRB) traded between $1.11 and $4.70 over the past 52 weeks and last traded at $1.21, 74.3% below its 52-week high. Over the past week it ranged between $1.11 and $1.37.

Past 12 Months

-1.6%

-15.4%

-54.2%

-58.6%

-65.1%

-65.8%

1W -$0.02

1M -$0.22

3M -$1.43

6M -$1.71

YTD -$2.26

1Y -$2.33

CLRB was -65.8% over the past year, -58.6% over six months, -65.1% year to date, -1.6% in the last week.

12 Months vs Market

CLRB

-65.8%

DIA

+10.6%

SPY

+11.8%

QQQ

+11.5%

IWM

+16.2%

Over the past 12 months CLRB returned -65.8% versus DIA (Dow) +10.6%, SPY (S&P 500) +11.8%, QQQ (Nasdaq 100) +11.5% and IWM (Russell 2000) +16.2%.

Volume & Liquidity 0.10× 3-mo avg

Today 9,249 3-mo avg 93.6K

99.8K

166.7K

93.6K

114.6K

YTD

358.3K

316.7K

CLRB most recently traded 9,249 shares against a 3-month average daily volume of 93.6K.

More News

November 04, 2026

Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Tuesday, November 10, 2026

November 02, 2026

Cellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More Than Eight Years in Heavily Pretreated DLBCL Patient Treated with Iopofosine I 131

October 27, 2026

Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenström Macroglobulinemia

October 15, 2026

Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenström Macroglobulinemia

September 29, 2026

Cellectar Biosciences (CLRB) Q2 2026 Earnings Call Transcript ↗

August 20, 2026

Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

August 13, 2026

Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026

July 30, 2026

Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers

July 15, 2026

Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting

June 01, 2026

Cellectar (CLRB) Q1 2026 Earnings Transcript ↗

May 14, 2026

Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

May 14, 2026

Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026

May 11, 2026

Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia

May 05, 2026

Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million

May 05, 2026

Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026

April 21, 2026

Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)

April 14, 2026

Cellectar (CLRB) Q4 2025 Earnings Call Transcript ↗

March 04, 2026

Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates

March 04, 2026

Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026

February 25, 2026

Cellectar Biosciences Expands Global Intellectual Property Estate

February 17, 2026

Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference

January 09, 2026

Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies

December 16, 2025